Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Annals of Hematology
Published in: Annals of Hematology 3/2022

01-03-2022 | Graft-Versus-Host Disease | Original Article

Elevated REG3α predicts refractory aGVHD in patients who received steroids-ruxolitinib as first-line therapy

Authors: Jingjing Yang, Bo Peng, Lu Wang, Xin Li, Fei Li, Xiangshu Jin, Mingyu Jia, Lingmin Xu, Liping Dou, Daihong Liu

Published in: Annals of Hematology | Issue 3/2022

Login to get access

Abstract

We started a single-arm, phase II, open-label, prospective clinical trial using steroids-ruxolitinib as the first-line therapy for intermediate- to high-risk aGVHD (NCT04397367). Here, we report the association of a biomarker panel (sST2, REG3α, sTNFR1, IL-6 and IL-8) with responses to GVHD therapy. The novel first-line therapy for 39 patients with newly diagnosed aGVHD consisted of 1 mg/kg methylprednisolone and 5 mg/day ruxolitinib. The serum concentrations of the biomarkers were prospectively detected at planned time points. Of the 39 patients, the complete response rate at day 28 was 82.05%. In patients who achieved CR, the concentrations of REG3α (P14 = 0.01; P28 = 0.10) and sTNFR1 (P14 = 0.42; P28 = 0.04) declined at day 14 and day 28 compared with the pre-enrolment levels. In refractory patients, the levels of REG3α at day 14 were higher than those pre-enrolment (P = 0.04). REG3α (P = 0.02) was elevated in the refractory patients compared with the patients achieving CR at day 14 after enrolment, while there was no significant difference in the levels of sST2, sTNFR1 or IL-6. Elevated REG3α levels may predict refractory aGVHD after novel first-line therapy with steroids-ruxolitinib.
Appendix
Available only for authorised users
Literature
1.
Wang H, Liu YC, Zhu CY, Yan F, Wang MZ, Chen XS, Wang XK, Pang BX, Li YH, Liu DH, Gao CJ, Liu SJ, Dou LP (2020) Chidamide increases the sensitivity of refractory or relapsed acute myeloid leukemia cells to anthracyclines via regulation of the HDAC3 -AKT-P21-CDK2 signaling pathway. Journal of experimental & clinical cancer research: CR 39(1):278CrossRef
2.
Dou L, Xu Q, Wang M, Xiao Y, Cheng L, Li H, Huang W, Mei J, Jing Y, Bo J, Liu D, Yu L (2019) Clinical efficacy of decitabine in combination with standard-dose cytarabine, aclarubicin hydrochloride, and granulocyte colony-stimulating factor in the treatment of young patients with newly diagnosed acute myeloid leukemia. Onco Targets Ther 12:5013–5023CrossRef
3.
Zhou L, Wang Q, Chen X, Fu L, Zhang X, Wang L, Deng A, Li D, Liu J, Lv N, Wang L, Li Y, Liu D, Yu L, Dou L (2017) AML1-ETO promotes SIRT1 expression to enhance leukemogenesis of t(8;21) acute myeloid leukemia. Exp Hematol 46:62–69CrossRef
4.
Flowers ME, Inamoto Y, Carpenter PA, Lee SJ, Kiem HP, Petersdorf EW, Pereira SE, Nash RA, Mielcarek M, Fero ML, Warren EH, Sanders JE, Storb RF, Appelbaum FR, Storer BE, Martin PJ (2011) Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. Blood 117(11):3214–3219CrossRef
5.
Zeiser R, Blazar BR (2017) Acute graft-versus-host disease - biologic process, prevention, and therapy. N Engl J Med 377(22):2167–2179CrossRef
6.
Rezvani AR, Storb RF (2012) Prevention of graft-vs-host disease. Expert opinion on pharmacotherapy 13(12):1737–1750CrossRef
7.
Levine JE, Paczesny S, Mineishi S, Braun T, Choi SW, Hutchinson RJ, Jones D, Khaled Y, Kitko CL, Bickley D, Krijanovski O, Reddy P, Yanik G, Ferrara JL (2008) Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease. Blood 111(4):2470–2475CrossRef
8.
Srinagesh HK, Özbek U, Kapoor U, Ayuk F, Aziz M, Ben-David K, Choe HK, DeFilipp Z, Etra A, Grupp SA, Hartwell MJ, Hexner EO, Hogan WJ, Karol AB, Kasikis S, Kitko CL, Kowalyk S, Lin JY, Major-Monfried H, Mielke S, Merli P, Morales G, Ordemann R, Pulsipher MA, Qayed M, Reddy P, Reshef R, Rösler W, Sandhu KS, Schechter T, Shah J, Sigel K, Weber D, Wölfl M, Wudhikarn K, Young R, Levine JE, Ferrara JLM (2019) The MAGIC algorithm probability is a validated response biomarker of treatment of acute graft-versus-host disease. Blood Adv 3(23):4034–4042CrossRef
9.
MacMillan ML, DeFor TE, Holtan SG, Rashidi A, Blazar BR, Weisdorf DJ (2020) Validation of Minnesota acute graft-versus-host disease Risk Score. Haematologica 105(2):519–524CrossRef
10.
Hartwell MJ, Özbek U, Holler E, Renteria AS, Major-Monfried H, Reddy P, Aziz M, Hogan WJ, Ayuk F, Efebera YA, Hexner EO, Bunworasate U, Qayed M, Ordemann R, Wölfl M, Mielke S, Pawarode A, Chen YB, Devine S, Harris AC, Jagasia M, Kitko CL, Litzow MR, Kröger N, Locatelli F, Morales G, Nakamura R, Reshef R, Rösler W, Weber D, Wudhikarn K, Yanik GA, Levine JE, Ferrara JL (2017) An early-biomarker algorithm predicts lethal graft-versus-host disease and survival. JCI insight 2(3):e89798CrossRef
11.
Ferrara JLM, Chaudhry MS (2018) GVHD: biology matters. Blood Adv 2(22):3411–3417CrossRef
12.
Chen X, Das R, Komorowski R, Beres A, Hessner MJ, Mihara M, Drobyski WR (2009) Blockade of interleukin-6 signaling augments regulatory T-cell reconstitution and attenuates the severity of graft-versus-host disease. Blood 114(4):891–900CrossRef
13.
Tawara I, Koyama M, Liu C, Toubai T, Thomas D, Evers R, Chockley P, Nieves E, Sun Y, Lowler KP, Malter C, Nishimoto N, Hill GR, Reddy P (2011) Interleukin-6 modulates graft-versus-host responses after experimental allogeneic bone marrow transplantation. Clinical cancer research : an official journal of the American Association for Cancer Research 17(1):77–88CrossRef
14.
Toubai T, Tanaka J, Paczesny S, Shono Y, Reddy P, Imamura M (2012) Role of cytokines in the pathophysiology of acute graft-versus-host disease (GVHD): are serum/plasma cytokines potential biomarkers for diagnosis of acute GVHD following allogeneic hematopoietic cell transplantation (Allo-HCT)? Curr Stem Cell Res Ther 7(3):229–239CrossRef
15.
Jagasia M, Perales MA, Schroeder MA, Ali H, Shah NN, Chen YB, Fazal S, Dawkins FW, Arbushites MC, Tian C, Connelly-Smith L, Howell MD, Khoury HJ (2020) Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial. Blood 135(20):1739–1749CrossRef
16.
Delgado-Martin C, Meyer LK, Huang BJ, Shimano KA, Zinter MS, Nguyen JV, Smith GA, Taunton J, Winter SS, Roderick JR, Kelliher MA, Horton TM, Wood BL, Teachey DT, Hermiston ML (2017) JAK/STAT pathway inhibition overcomes IL7-induced glucocorticoid resistance in a subset of human T-cell acute lymphoblastic leukemias. Leukemia 31(12):2568–2576CrossRef
17.
Przepiorka D, Luo L, Subramaniam S, Qiu J, Gudi R, Cunningham LC, Nie L, Leong R, Ma L, Sheth C, Deisseroth A, Goldberg KB, Blumenthal GM, Pazdur R (2020) FDA Approval summary: ruxolitinib for treatment of steroid-refractory acute graft-versus-host disease. Oncologist 25(2):e328–e334CrossRef
18.
Zeiser R, von Bubnoff N, Butler J, Mohty M, Niederwieser D, Or R, Szer J, Wagner EM, Zuckerman T, Mahuzier B, Xu J, Wilke C, Gandhi KK, Socié G (2020) Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease. N Engl J Med 382(19):1800–1810CrossRef
19.
Umehara K, Huth F, Jin Y, Schiller H, Aslanis V, Heimbach T, He H (2019) Drug-drug interaction (DDI) assessments of ruxolitinib, a dual substrate of CYP3A4 and CYP2C9, using a verified physiologically based pharmacokinetic (PBPK) model to support regulatory submissions. Drug metabolism and personalized therapy 34 (2).
20.
Shi JG, Chen X, Emm T, Scherle PA, McGee RF, Lo Y, Landman RR, McKeever EG Jr, Punwani NG, Williams WV, Yeleswaram S (2012) The effect of CYP3A4 inhibition or induction on the pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in healthy volunteers. J Clin Pharmacol 52(6):809–818CrossRef
21.
Aslanis V, Umehara K, Huth F, Ouatas T, Bharathy S, Butler AA, Zhou W, Gadbaw B (2019) Multiple administrations of fluconazole increase plasma exposure to ruxolitinib in healthy adult subjects. Cancer Chemother Pharmacol 84(4):749–757CrossRef
22.
Ogama Y, Mineyama T, Yamamoto A, Woo M, Shimada N, Amagasaki T, Natsume K (2013) A randomized dose-escalation study to assess the safety, tolerability, and pharmacokinetics of ruxolitinib (INC424) in healthy Japanese volunteers. Int J Hematol 97(3):351–359CrossRef
23.
Shi JG, Chen X, McGee RF, Landman RR, Emm T, Lo Y, Scherle PA, Punwani NG, Williams WV, Yeleswaram S (2011) The pharmacokinetics, pharmacodynamics, and safety of orally dosed INCB018424 phosphate in healthy volunteers. J Clin Pharmacol 51(12):1644–1654CrossRef
24.
Hou C, Dou L, Jia M, Li F, Wang S, Gao X, Wang L, Jin X, Wang L, Gao C, Liu D (2021) Ruxolitinib combined with corticosteroids as first-line therapy for acute graft-versus-host disease in haploidentical peripheral blood stem cell transplantation recipients. Transplantation and cellular therapy 27(1):75.e71-75.e10CrossRef
25.
Dou L, Hou C, Ma C, Li F, Gao X, Huang W, Wang S, Gao C, Yu L, Liu D (2020) Reduced risk of chronic GVHD by low-dose rATG in adult matched sibling donor peripheral blood stem cell transplantation for hematologic malignancies. Ann Hematol 99(1):167–179CrossRef
26.
Dou LP, Li HH, Wang L, Li F, Huang WR, Yu L, Liu DH (2018) Efficacy and safety of unmanipulated haploidentical related donor allogeneic peripheral blood stem cell transplantation in patients with relapsed/refractory acute Myeloid Leukemia. Chin Med J 131(7):790–798CrossRef
27.
Li HH, Li F, Gao CJ, Huang WR, Bo J, Dou LP, Wang LL, Jing Y, Wang L, Li WJ, Yu L, Liu DH (2017) Similar incidence of severe acute GVHD and less severe chronic GVHD in PBSCT from unmanipulated, haploidentical donors compared with that from matched sibling donors for patients with haematological malignancies. Br J Haematol 176(1):92–100CrossRef
28.
Dou LP, Hou C, Yang T, Cheng LC, Bo J (2020) Characteristics of pathogens detected in adults with hematological malignancies and nosocomial infections in the tropics. Chin Med J 133(14):1735–1737CrossRef
29.
Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, Thomas ED (1995) 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant 15(6):825–828PubMed
30.
Kumar S, Tzimas MN, Griswold DE, Young PR (1997) Expression of ST2, an interleukin-1 receptor homologue, is induced by proinflammatory stimuli. Biochem Biophys Res Commun 235:474–478CrossRef
31.
Vander Lugt MT, Braun TM, Hanash S et al (2013) ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death. N Engl J Med 369:529–539CrossRef
32.
Presland RB (2017) Application of proteomics to graft-versus-host disease: from biomarker discovery to potential clinical applications. Expert Rev Proteomics 14:997–1006CrossRef
33.
Ferrara JL, Harris AC, Greenson JK et al (2011) Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease. Blood 118:6702–6708CrossRef
34.
Major-Monfried H, Renteria AS, Pawarode A, Reddy P, Ayuk F, Holler E, Efebera YA, Hogan WJ, Wölfl M, Qayed M, Hexner EO, Wudhikarn K, Ordemann R, Young R, Shah J, Hartwell MJ, Chaudhry MS, Aziz M, Etra A, Yanik GA, Kröger N, Weber D, Chen YB, Nakamura R, Rösler W, Kitko CL, Harris AC, Pulsipher M, Reshef R, Kowalyk S, Morales G, Torres I, Özbek U, Ferrara JLM, Levine JE (2018) MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD. Blood 131(25):2846–2855CrossRef
Metadata
Title
Elevated REG3α predicts refractory aGVHD in patients who received steroids-ruxolitinib as first-line therapy
Authors
Jingjing Yang
Bo Peng
Lu Wang
Xin Li
Fei Li
Xiangshu Jin
Mingyu Jia
Lingmin Xu
Liping Dou
Daihong Liu
Publication date
01-03-2022
Publisher
Springer Berlin Heidelberg
Published in
Annals of Hematology / Issue 3/2022
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-021-04727-1

Other articles of this Issue 3/2022

Annals of Hematology 3/2022 Go to the issue

Letter to the Editor

TTP or complement-mediated TMA or both? A rare diagnosis and report of a novel plasminogen gene variant

Letter to the Editor

Successful ibrutinib treatment for central nervous system relapse of chronic lymphocytic leukemia after allogeneic hematopoietic stem cell transplantation

Letter to the Editor

Acquired thrombotic thrombocytopenic purpura after first vaccination dose of BNT162b2 mRNA COVID-19 vaccine

Original Article

Effectiveness of prophylactic antiviral therapy in reducing HBV reactivation for HBsAg-positive recipients following allogeneic hematopoietic stem cell transplantation: a multi-institutional experience from an HBV endemic area

Original Article

Management of herpesvirus reactivations in patients with solid tumours and hematologic malignancies: update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO) on herpes simplex virus type 1, herpes simplex virus type 2, and varicella zoster virus

Letter to the Editor

Venetoclax and decitabine in refractory TP53-mutated early T-cell precursor acute lymphoblastic leukemia
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits